Efficacy of QR678 Neo ® hair growth factor formulation for the treatment of hair loss in Covid‐19‐induced persistent Telogen Effluvium—A prospective, clinical, single‐blind study

There is a growing interest in alopecia prevention strategies, as the number of alopecia patients is increasing. We examine the efficacy of herbal medicine for hair growth promotion/hair loss inhibition in two cell lines via Western blot and high-content screening (HCS). Nine herbal extracts were obtained from three different herbal medicine mixtures using 3 different extraction methods. Five target proteins—IGF-1 (insulin-like growth factor–1), TGF-β2 (transforming growth factor–β2), VEGF (vascular endothelial growth factor), DKK-1 (Dickkopf-1), and Wnt5α—were observed for the assessment of hair growth promotion/hair loss inhibition efficacy. The efficacies of nine extracts were compared with minoxidil as control. Efficacy was defined as a rise in the expression levels of IGF-1, VEGF, and Wnt5α but a decrease in DKK-1 and TGF-β2. Intracellular concurrent imaging of these proteins was successfully achieved using HCS, employing visible-to-near infrared probing based on quantum-antibody conjugates and hypermulticolor imaging.

Download Full-text

Macrophage-Derived Extracellular Vesicle Promotes Hair Growth

Cells ◽

10.3390/cells9040856 ◽

2020 ◽

Vol 9 (4) ◽

pp. 856 ◽

Cited By ~ 5

Author(s):

Ramya Lakshmi Rajendran ◽

Prakash Gangadaran ◽

Chang Hoon Seo ◽

Mi Hee Kwack ◽

Ji Min Oh ◽

...

Keyword(s):

Growth Factor ◽

Hair Loss ◽

Hair Growth ◽

Keratinocyte Growth Factor ◽

Hair Shaft ◽

Hair Follicles ◽

Wnt Proteins ◽

Short Period ◽

Phosphorylated Akt

Hair loss is a common medical problem affecting both males and females. Dermal papilla (DP) cells are the ultimate reservoir of cells with the potential of hair regeneration in hair loss patients. Here, we analyzed the role of macrophage-derived Wnts (3a and 7b) and macrophage extracellular vesicles (MAC-EVs) in promoting hair growth. We studied the proliferation, migration, and expression of growth factors of human-DP cells in the presence or absence of MAC-EVs. Additionally, we tested the effect of MAC-EV treatment on hair growth in a mouse model and human hair follicles. Data from western blot and flow cytometry showed that MAC-EVs were enriched with Wnt3a and Wnt7b, and more than 95% were associated with their membrane. The results suggest that Wnt proteins in MAC-EVs activate the Wnt/β-catenin signaling pathways, which leads to activation of transcription factors (Axin2 and Lef1). The MAC-EVs significantly enhanced the proliferation, migration, and levels of hair-inductive markers of DP cells. Additionally, MAC-EVs phosphorylated AKT and increased the levels of the survival protein Bcl-2. The DP cells treated with MAC-EVs showed increased expression of vascular endothelial growth factor (VEGF) and keratinocyte growth factor (KGF). Treatment of Balb/c mice with MAC-EVs promoted hair follicle (HF) growth in vivo and also increased hair shaft size in a short period in human HFs. Our findings suggest that MAC-EV treatment could be clinically used as a promising novel anagen inducer in the treatment of hair loss.

Download Full-text

The Therapeutic Response of Platelet Rich Plasma (PRP) for Androgenetic Alopecia Showed No Correlation with Growth Factors and Platelet Number

Blood ◽

10.1182/blood.v128.22.2637.2637 ◽

2016 ◽

Vol 128 (22) ◽

pp. 2637-2637 ◽

Cited By ~ 2

Author(s):

Bruno Lima Rodrigues ◽

Silmara Aparecida De Lima Montalvão ◽

Joyce Annichinno-Bizzacchi ◽

Rebeca Cancela ◽

Francesca Silva ◽

...

Keyword(s):

Growth Factors ◽

Growth Factor ◽

Hair Loss ◽

Hair Growth ◽

Therapeutic Response ◽

Platelet Rich Plasma ◽

Androgenetic Alopecia ◽

Autologous Serum ◽

Platelet Number ◽

The Mean

Abstract Background: Androgenetic alopecia (AGA) is characterized by a pattern hair loss. Currently, treatment with platelet-rich plasma (PRP) has shown promising results due to the growth factors (GFs) released by the platelets. However, the analysis of therapeutic response according to GFs levels and platelet number in PRP has not been established. Objective: Investigate the therapeutic response to treatment of AGA using a standard method of PRP preparation, and the relation with GFs levels and platelet number. Methods: Inclusion criteria comprised diagnosis of AGA-III-vertex profile according to the Norwood-Hamilton scale, age between 18 and 50 years. Exclusion criteria comprised female gender, previous hair transplantation, any disease related to hair loss such as thyroid disease and/or iron deficiency, neoplasia present or past, kidney, liver, infectious, hematologic or rheumatoid disease, use of antiplatelet and/or anti-inflammatory drugs. All patients provided written informed consent approved by the ethic committee from the Faculty of Medical Sciences of the State University of Campinas (UNICAMP). The protocol comprised 20 subcutaneous injections of 100 µL in the scalp totaling 4 applications every fifteen days, with evaluation performed pretreatment (t0), 45 (t1) and 150 (t2) days after the start of the protocol. The endpoints for therapeutic response were hair growth and increase of percentage of anagen hairs evaluated by TrichoScan. For each patient 40 mL of peripheral blood were collected in ACD tubes. L-PRP (PRP with leukocytes) was performed, with double centrifugation (300 g for 5 minutes, and 700 g for 17 minutes). The platelets were counted in the baseline and in the PRP samples. PRP was activated with autologous serum. The platelet-derived growth factors (PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) were measured by Luminex technique (Millipore®, USA), in two different PRP samples from each patient. Results: During the period of August to December of 2014, 15 male patients were included in the study. The median of platelets in PRP was increased by 5 folds in all four PRP preparations with a minimum of 728.9 and maximum 1.901,90 x 106 cel/uL, and median values of 1.082 x 106 cel/uL (range 608 - 2.023). The baseline number of platelets and PRP preparation showed a significant correlation (r = 0.839, p < 0.0001). The variability of platelet numbers from each individual during the four applications was 19.7% with a minimum of 0.50% and a maximum 56.3%. GF quantification of two different PRP preparations showed a similar intra-individual variation, with a mean of variability coefficient of 18.4% for VEGF, 20.9% for PDGF, and 21.6% for EGF (Table 1). EGF and PDGF concentrations showed a significant correlation to PRP platelets number (r = 0.8287 and P < 0.0001, and r = 0.6925 and P=0.0014, respectively) (Figure 1). Our results showed a significant increase in hair count (P = 0.0018) and anagen hairs (P = 0.0070) in 86.6% and 53.3% of patients, respectively. However, no correlation was found between platelet counts and GFs levels with therapeutic response. The patients who presented high levels of GFs did not show better results for hair growth or anagen hair than who presented lower levels. Conclusion: Our results corroborate previous studies that showed PRP as a quite promising therapeutic option for AGA, up to 3 months after the injections. However, there was a lack of correlation between the therapeutic responses and platelet numbers or GFs levels. Although, the GFs were not considered biomarker for PRP, it may play an important role in the PRP therapeutic effect. In addition, our results suggest that the PRP effects depend on an orchestration between many mechanisms involved in the increase of number of hairs and its growth. Furthermore, local receptors might present a central role in this response. Graphs of correlation between the platelet mean in PRP and the mean of the growth factor concentrations Graphs of correlation between the platelet mean in PRP and the mean of the growth factor concentrations Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Influence of Vitamin E on Plasma Malondialdehyde- Like Material in Man

Thrombosis and Haemostasis ◽

10.1055/s-0038-1661098 ◽

1984 ◽

Vol 51 (03) ◽

pp. 347-348 ◽

Cited By ~ 12

Author(s):

C Cordova ◽

A Musca ◽

F Violi ◽

C Alessandri ◽

A Ghiselli ◽

...

Keyword(s):

Vitamin E ◽

Healthy Subjects ◽

Placebo Treatment ◽

Blind Study ◽

Single Blind ◽

Plasma Malondialdehyde

SummaryThe behaviour of plasma malondialdehyde-like material (MDA-LM) was evaluated in 13 healthy subjects by a single-blind study that consisted of placebo (30 days), vitamin E treatment (300 mg/day) (30 days) and placebo (30 days). The study demonstrated that MDA-LM did not change during placebo treatment while it significantly decreased after vitamin E administration.

Download Full-text

Hair Growth in a Patient with Alopecia Areata on Tocilizumab

Skin Appendage Disorders ◽

10.1159/000516300 ◽

2021 ◽

pp. 1-5

Author(s):

Chloe J. Walker ◽

Kelly E. Flanagan ◽

James T. Pathoulas ◽

Isabel Pupo Wiss ◽

Maryanne M. Senna

Keyword(s):

Monoclonal Antibody ◽

Autoimmune Disease ◽

Hair Loss ◽

Alopecia Areata ◽

Interleukin 6 ◽

Hair Growth ◽

Posterior Uveitis ◽

Case Presentation ◽

Antibody Targeting ◽

Growth Changes

Introduction: Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. Case Presentation: Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. Discussion: Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.

Download Full-text

Topical bromfenac reduces multiple inflammatory cytokines in the aqueous humour of pseudophakic patients

Scientific Reports ◽

10.1038/s41598-021-85495-w ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Takehiro Matsumura ◽

Kentaro Iwasaki ◽

Shogo Arimura ◽

Ryuji Takeda ◽

Yoshihiro Takamura ◽

...

Keyword(s):

Growth Factor ◽

Inflammatory Cytokines ◽

Aqueous Humour ◽

Ophthalmic Solution ◽

Vascular Endothelial ◽

Monocyte Chemoattractant Protein 1 ◽

Monocyte Chemoattractant ◽

Before And After ◽

Endothelial Growth Factor ◽

Single Blind

AbstractIntraocular surgery is associated with increased ocular inflammation. If maintained for a prolonged period after surgery, this inflammation can cause various complications, including subconjunctival fibrosis and bleb scarring. This clinical trial was a prospective, randomised, single-blind, interventional study comparing the efficacy and safety of 0.1% bromfenac sodium ophthalmic solution and 0.02% fluorometholone ophthalmic suspension in the inhibition of multiple inflammatory cytokines in the aqueous humour of 26 patients with pseudophakic eyes who had undergone phacoemulsification and intraocular lens implantation. The patients were randomly assigned to one of the trial drugs, and aqueous humour samples were collected before and after drug administration. Platelet-derived growth factor-AA levels significantly decreased in both drug groups, but they were significantly higher in the fluorometholone group than in the bromfenac group (P = 0.034). Bromfenac also significantly decreased vascular endothelial growth factor level (P = 0.0077), as well as monocyte chemoattractant protein-1 level (P = 0.013), which was elevated for a prolonged period after phacoemulsification. These data suggest that bromfenac is useful to alleviate prolonged microenvironmental alterations in the aqueous humour of pseudophakic eyes.

Download Full-text

An osteopontin‐derived peptide inhibits human hair growth at least in part by decreasing fibroblast growth factor‐7 production in outer root sheath keratinocytes

British Journal of Dermatology ◽

10.1111/bjd.18479 ◽

2019 ◽

Vol 182 (6) ◽

pp. 1404-1414 ◽

Cited By ~ 1

Author(s):

M. Alam ◽

M. Bertolini ◽

J. Gherardini ◽

A. Keren ◽

L. Ponce ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Human Hair ◽

Hair Growth ◽

Fibroblast Growth ◽

Outer Root Sheath ◽

Root Sheath ◽

Outer Root Sheath Keratinocytes

Download Full-text

Anesthetic Efficacy of a Combination of 0.5 M Mannitol Plus 127.2 mg of Lidocaine With 50 μg Epinephrine in Inferior Alveolar Nerve Blocks: A Prospective Randomized, Single-Blind Study

Anesthesia Progress ◽

10.2344/11-00040.1 ◽

2013 ◽

Vol 60 (1) ◽

pp. 3-10 ◽

Cited By ~ 7

Author(s):

Steven Smith ◽

Al Reader ◽

Melissa Drum ◽

John Nusstein ◽

Mike Beck

Keyword(s):

Postoperative Pain ◽

Inferior Alveolar Nerve ◽

Blind Study ◽

Maximum Output ◽

Nerve Blocks ◽

Posterior Teeth ◽

Solution Deposition ◽

The Times ◽

Pulpal Anesthesia ◽

Single Blind

Abstract The purpose of this prospective, randomized, single-blind study was to determine the anesthetic efficacy of 127.2 mg lidocaine with 50 μg epinephrine compared to 127.2 mg lidocaine with 50 μg epinephrine plus 0.5 M mannitol in inferior alveolar nerve (IAN) blocks. Forty subjects randomly received 2 IAN blocks consisting of a 3.18 mL formulation of 127.2 mg lidocaine with 50 μg epinephrine and a 5 mL formulation of 127.2 mg lidocaine with 50 μg epinephrine (3.18 mL) plus 0.5 M mannitol (1.82 mL) in 2 separate appointments spaced at least 1 week apart. Mandibular anterior and posterior teeth were blindly electric pulp tested at 4-minute cycles for 60 minutes postinjection. Pain of solution deposition and postoperative pain were also measured. No response from the subject to the maximum output (80 reading) of the pulp tester was used as the criterion for pulpal anesthesia. Total percent pulpal anesthesia was defined as the total of all the times of pulpal anesthesia (80 readings) over the 60 minutes. One hundred percent of the subjects had profound lip numbness with both inferior alveolar nerve blocks. The results demonstrated that a 5 mL formulation of 127.2 mg lidocaine with 50 μg epinephrine plus 0.5 M mannitol was significantly better than the 3.18 mL formulation of 127.2 mg lidocaine with 50 μg epinephrine for all teeth. Solution deposition pain and postoperative pain were not statistically different between the lidocaine/mannitol formulation and the lidocaine formulation without mannitol. We concluded that adding 0.5 M mannitol to a lidocaine with epinephrine formulation was significantly more effective in achieving a greater percentage of total pulpal anesthesia than a lidocaine formulation without mannitol.

Download Full-text